NEW YORK – Chinese molecular diagnostics firm AnchorDx aims to develop a $100 circulating tumor DNA (ctDNA) screening test to detect six major cancer types at an early stage. The goal is to launch the test in the US and Chinese markets once it has been approved by regulatory authorities in those countries.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.